Pdt Partners, LLC Erasca, Inc. Transaction History

Pdt Partners, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$1.97 - $2.91 $103,125 - $152,332	-52,348 Reduced 55.1%	42,651 $84,000
Q2 2023 Aug 14, 2023	SELL	$2.57 - $3.3 $179,123 - $230,003	-69,698 Reduced 42.32%	94,999 $262,000
Q1 2023 May 15, 2023	BUY	$2.74 - $4.44 $178,042 - $288,506	64,979 Added 65.16%	164,697 $495,000
Q4 2022 Feb 14, 2023	BUY	$3.89 - $8.57 $387,903 - $854,583	99,718 New	99,718 $429,000

141

229M

28.7K

117K

Ticker ERAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,147,000
Market Cap $204M
Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.